Form 4: Pfizer Director James C. Smith Reports Acquisition of Phantom Stock Units

Director James C. Smith reports acquiring phantom stock units in Pfizer, Inc. through a nonfunded deferred compensation plan.

Summary

• On April 25, 2024, James C. Smith, a director of Pfizer Inc., acquired 8,115.598 phantom stock units.
• The acquisition was made pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of common stock and will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• Following the transaction, Smith directly owns 128,555.69 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices and aligns director interests with company performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The Nonfunded Deferred Compensation Plan allows directors to defer compensation, potentially offering tax advantages.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of phantom stock units by a director can positively influence shareholder confidence by aligning management's interests with those of the shareholders.

Key Dates